SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
9989
1. 20.8% 6,422.8 5,315.7
2. 2,019.6 2,016.8
3. 77.1% 2,675.2
1,510.7
4. 1.7% 2,747.7
2,700.9
5. CDMO 2.0% 813.1 797.4
17.3% 692.9
590.5
6.
580.9
1
4 6,422,761 5,315,685
(4,403,177) (3,298,849)
2,019,584 2,016,836
5 (13,682) 365,378
(424,828) (408,901)
(668,326) (598,078)
(76,709) (15,194)
(200,706) –
(5,463) (2,385)
6 (210,074) (260,824)
(2,125) 231,004
7 417,671 1,327,836
8 (42,166) (306,204)
375,505 1,021,632
382,569 1,024,210
(7,064) (2,578)
9
0.26 0.76
0.26 0.76
2
375,505 1,021,632
(36,157) (181,924)
(424) (1,642)
(36,581) (183,566)
(16,137) 6,835
892 (25,050)
(15,245) (18,215)
(51,826) (201,781)
323,679 819,851
331,083 823,914
(7,404) (4,063)
3
2,526,672 2,623,449
239,854 186,191
2,152,201 2,202,566
472,969 512,370
1,292,629 1,631,183
474,885 619,953
994,500 1,747,437
173,436 83,936
206,016 290,086
8,533,162 9,897,171
4,670,575 3,168,249
10 1,603,128 1,666,216
14,993 20,477
571,431 697,600
45,301 49,235
980,909 821,257
248 6,949
11,581 80
1,440,000 1,368,416
1,479,633 1,330,245
10,817,799 9,128,724
11 385,787 239,218
707,848 526,140
377,814 256,950
2,573,801 2,481,977
42,316 74,836
6,223 8,113
31,754 25,600
4,125,543 3,612,834
4
6,692,256 5,515,890
15,225,418 15,413,061
2,944,635 3,085,857
16,673 18,744
342,865 427,673
138,020 130,936
9,068 9,218
104,001 51,643
3,555,262 3,724,071
11,670,156 11,688,990
12 1,467,296 1,467,296
10,090,559 10,102,096
11,557,855 11,569,392
112,301 119,598
11,670,156 11,688,990
5
CDMO
(i) (ii)API
API API (iii) API
Cytovance Biologics, Inc.
SPL
Acquisition Corp. SPL
CDMO
Delta Omicron
8.1%
114.4
6
API
20.8% 6,422.8
5,315.7 382.6
62.6%
Kymab
585.7
RVX
580.9 5.7%
1,479.6 11.2%
6,422.8 20.8%
382.6
1,024.2 62.6%
7
(%)
5,567,901 4,456,472 24.9%
2,675,188 1,510,731 77.1%
API 2,747,671 2,700,886 1.7%
(1)
145,042 244,855 (40.8%)
CDMO 813,104 797,387 2.0%
(2)
41,756 61,826 (32.5%)
6,422,761 5,315,685 20.8%
(1) API
(2)
(i) (ii) API (iii) CDMO
77.1% 1,164.5 2,675.2
41.7%
40
1.8 74.7%
8
49.3% 59.3%
FDA
1,000
FDA
200%
281.7%
9
60
40
16.2%
400
(CP) EMA
20% 65%
API
2,747.7
2,700.9 42.8% 27.0%
API API
API 48.8% 31.2%
10
CDMO
CDMO 813.1 797.4
5.7 32.0%
CDMO 692.9
17.3% 45.5%
25.3% 85.2% 14.7
45.5% CDMO
mRNA
mRNA CDMO
KPI CDMO
11
SPL
CDMO
CDMO
CDMO
CDMO 100
AR-301 (Salvecin)
AR-301 IgG1 (mAb)
Aridis Pharmaceuticals, Inc.
ARDS III
(VAP)
I/II
AR-301
AR-301 FDA EMA
Oregovomab
Oregovomab CA125
OncoQuest Inc. OncoQuest II
II
Oregovomab
II (PFS)
41.8 PFS 12.2 HR 0.46 (95% Cl: 0.28, 0.77)
(OS) HR 0.35 (95% Cl: 0.16, 0.76) Oregovomab
FDA EMA
12
Oregovomab III
17 140 602
Oregovomab pre-IND Oregovomab
III 142 7
pre-IND CDE
6 III MRCT
RVX-208 (Apabetalone)
RVX-208 (BET)
Resverlogix Corp.
RVX RVX-208 III
BETonMACE) II
(HDL)
FDA FDA III
Apabetalone FDA
H1710
H1710
(HBD)
H1710
(HS)
H1710 IND
H1710
IND
13
Omicorn
(GDP)
API
API
API
14
CDMO
CDMO
CDMO
15
(%) (%) (%)
5,567,901 86.7% 4,456,472 83.8% 24.9%
2,675,188 41.7% 1,510,731 28.4% 77.1%
API 2,747,671 42.8% 2,700,886 50.8% 1.7%
(1)
145,042 2.2% 244,855 4.6% (40.8%)
CDMO 813,104 12.7% 797,387 15.0% 2.0%
(2)
41,756 0.6% 61,826 1.2% (32.5%)
6,422,761 100% 5,315,685 100.0% 20.8%
1,111.4 5,567.9
86.7% 4,456.5
83.8%
77.1%
1,104.4 4,403.2
3,298.8
API
16
(%) (%)
1,717,940 30.9% 1,755,073 39.4%
981,971 36.7% 724,150 47.9%
API 742,049 27.0% 1,078,164 39.9%
(1)
(6,080) (4.2%) (47,241) (19.3%)
CDMO 259,803 32.0% 209,832 26.3%
(2)
41,840 100.2% 51,931 84.0%
2,019,584 31.4% 2,016,836 37.9%
(1) API
(2)
2.7 2,019.6
2,016.8 37.9%
6.5 31.4% API
50.7 210.1
260.8 19.4%
42.2
306.2 86.2%
17
382.6
1,024.2 62.7%
0.26
0.76 65.8%
18
1,479.6
1,330.2
2,573.8
2,482.0
2,944.6 3,085.9
2,480.1
2,563.4
19,351.0
19,025.9 7,680.8
7,336.9
39.7% 38.6%
93.7%
86.7%
19
5,518,436 5,567,834
135,755 77,243
5,654,191 5,645,077
(11,581) (80)
5,642,610 5,644,997
3,268,166 2,481,977
1,604,635 885,698
143,412 1,652,246
502,223 547,913
5,518,436 5,567,834
3,840.0
3,675.5
1,610.7
1,612.3
67.7 280.0
20
1.
002399.SZ
H
9989 21
30 47 4724
2.1
21
(a)
(b)
(c)
(i) (ii)
(iii) (i)
(ii) (iii)
2.2
9
39
7
4
16
16
22
(a)
9 39 7
4 16
9
24
LIBOR
LIBOR
(b) 16
23
3.
(a)
(b) API API API
(c) CDMO
(d)
24
API CDMO
2,675,188 2,747,671 813,104 186,798 6,422,761
1,356,682 3,520,136 3,892 301,906 5,182,616
4,031,870 6,267,807 816,996 488,704 11,605,377
(5,182,616)
6,422,761
849,751 929,488 259,209 70,788 2,109,236
(89,652)
(13,682)
(424,828)
(668,326)
(76,709)
(200,706)
(5,463)
(210,074)
(2,125)
417,671
25
API CDMO
3,624,171 11,096,799 2,080,120 1,272,449 18,073,539
(5,627,400)
6,904,822
19,350,961
2,408,652 2,753,548 421,601 2,741,219 8,325,020
(6,334,993)
5,690,778
7,680,805
(4,770) (52,174) (18,375) (1,390) (76,709)
50,782 86,367 75,438 94,207 306,794
472,969
2,580 80,118 67,025 26,298 176,021
26
API CDMO
1,510,731 2,700,886 797,387 306,681 5,315,685
1,782,320 1,861,116 32,500 249,999 3,925,935
3,293,051 4,562,002 829,887 556,680 9,241,620
(3,925,935)
5,315,685
636,689 1,161,446 218,719 36,947 2,053,801
(36,965)
365,378
(408,901)
(598,078)
(15,194)
(2,385)
(260,824)
231,004
1,327,836
27
API CDMO
3,084,149 10,155,357 2,113,756 1,261,697 16,614,959
(5,257,920)
7,668,856
19,025,895
1,875,201 2,315,599 315,019 2,484,552 6,990,371
(5,552,972)
5,899,506
7,336,905
(2,854) (10,515) (1,277) (548) (15,194)
48,323 74,873 51,107 97,853 272,156
1,631,183
19,732 24,879 95,087 94,890 234,588
28
(a)
187,981 51,404
993,169 894,076
3,469,218 2,904,348
552,243 514,511
1,220,150 951,346
6,422,761 5,315,685
(b)
2,908,216 3,725,102
3,368,616 3,546,915
141,086 171,057
472,423 2,771
10%
651,052,000
10%
769,183,000
29
4.
(i)
API CDMO
2,675,188 2,747,671 – 145,042 5,567,901
CDMO – – 813,104 – 813,104
– – – 41,756 41,756
2,675,188 2,747,671 813,104 186,798 6,422,761
2,675,188 2,747,671 – 145,042 5,567,901
– – 111,924 9,326 121,250
– – 701,180 32,430 733,610
2,675,188 2,747,671 813,104 186,798 6,422,761
30
API CDMO
1,510,731 2,700,886 – 244,855 4,456,472
CDMO – – 797,387 – 797,387
– – – 61,826 61,826
1,510,731 2,700,886 797,387 306,681 5,315,685
1,510,731 2,700,886 – 244,855 4,456,472
– – 220,788 36,392 257,180
– – 576,599 25,434 602,033
1,510,731 2,700,886 797,387 306,681 5,315,685
31
4,960 3,642
CDMO 257,228 197,544
262,188 201,186
(ii)
CDMO
15
FFS
CDMO
1,194,897 1,048,314
32
5.
54,857 34,647
* 2,072 2,072
** 21,794 44,679
28,575 14,590
15,488 16,561
122,786 112,549
(205,044) (248,832)
5,761 5,444
66,065 506,936
(4,181) 20,480)
(5,105) (1)
1,744 5,972
4,292 3,790
(136,468) 252,829
(13,682) 365,378
*
**
33
6.
121,352 147,240
76,406 96,248
3,873 4,231
8,443 13,105
210,074 260,824
34
7.
3,849,960 2,701,311
553,217 597,538
217,492 220,033
37,782 35,212
51,520 52,123
* 221,099 160,008
7,050 5,700
– 32,101
557,892 582,211
126,694 117,290
2,315 1,454
(54,857) (34,647)
210,074 260,824
1,744 5,972
(28,575) (14,590)
(15,488) (16,561)
205,044 248,832
(5,761) (5,444)
4,181 20,480
(66,065) (506,936)
5,105 1
76,709 15,194
34,919 55,879
200,706 –
*
35
8.
61,843 71,311
127,598 52,225
14,106 1,939
1,098 8,055
204,645 133,530
(99,301) 99,594
(66,608) 51,029
3,430 22,051
(162,479) 172,674
42,166 306,204
36
9.
1,467,296,204 1,353,329,463
382,569 1,024,210
1,467,296,204 1,353,329,463
10.
1,664,473 1,661,300
10,010 35,030
(71,355) (30,114)
1,603,128 1,666,216
37
1,549,707 1,630,918
88,504 40,309
36,070 18,391
202 6,712
1,674,483 1,696,330
(71,355) (30,114)
1,603,128 1,666,216
30,114 21,721
53,651 10,589
(11,940) (2,144)
(470) (52)
71,355 30,114
11.
385,787 239,218
38
379,298 236,702
4,292 1,774
1,518 709
679 33
385,787 239,218
30 90
12.
1,467,296,204 1,467,296,204 1,467,296 1,467,296
1,247,201,704 1,247,202
H 220,094,500 220,094
1,467,296,204 1,467,296
39
H
H H
3,538.3
30% 1,061.5
30% 1,061.5
20% 707.7
20% 707.7
2,434.9
1,034.4
76.7
2,427.3
H
1,061.5 1,034.4 27.1
3
1,061.5 – 1,061.5
3
707.7 – 707.7
3
707.7 76.7 631.0
3
3,538.4 1,111.1 2,427.3
40
5%
1,528
684.6 699.5
41
COVID-19
13.49(1) 13.49(2)
42
(i)
(ii)
(iii)
(http://www.hepalink.com/)
(http://www.hkexnews.hk) H
43